Off-Label Communications: US FDA Won't Impede Discussions With Payers, Gottlieb Says
Executive Summary
Guidance, to be issued 'very soon,' will provide a safe harbor for discussions between manufacturers and payers about off-label drug uses, Commissioner Scott Gottlieb says.
You may also be interested in...
Industry Communications With Payors: US FDA Okays Info On Investigational Drugs
Draft guidance provides clarity on what health care economic information firms can provide to payors, formulary committees and similar entities.
Off-Label Communication: When Does It Align With Approved Labeling?
US FDA draft guidance offers three-factor test to determine when communication about a medical product is consistent with labeling; information on patient-reported outcomes and mechanism of action are okay.
Pfizer Testing Warranty Offer With Xalkori, May Expand It To ‘Multiple’ Products
Company seeks to avoid Medicaid “best price” implications by administering the program through an insurance policy with AIG, which is handling claims for refunds and processing payments.